Founded by Dr. V. Margaret Jackson in ByoMassTx, short for ByoMass Therapeutics, is a preclinical pharmaceutical company developing novel biologic and small molecule drugs to modulate specific members of the TGF-β superfamily, for the treatment of orphan and common diseases of high unmet medical need.
×
BYOMass Therapeutics � selective TGF-beta inhibitors
© 2021 - Lifespan Extension Advocacy Foundation - LIFESPAN2023
The opinions expressed in interviews or commentary in articles appearing on this site are those of the subject or subjects and do not necessarily reflect the views of LEAF/Lifespan.io, its directors, officers or employees.
Powered by MMD